Overview
Extended-spectrum beta-lactamase (ESBL) producing Proteus mirabilis infections pose significant challenges in clinical settings due to their resistance to commonly used beta-lactam antibiotics. These infections are often part of a broader spectrum of ESBL-producing Enterobacteriaceae (ESBL-E) that includes Escherichia coli and Klebsiella pneumoniae. Epidemiological studies highlight the persistence and spread of ESBL-E among hospitalized and outpatient populations, emphasizing the need for robust infection control measures and targeted treatment strategies. The clinical presentation can range from asymptomatic carriage to severe infections, necessitating careful diagnostic approaches and tailored management plans. This guideline synthesizes current evidence to provide clinicians with a comprehensive framework for addressing ESBL-producing Proteus mirabilis infections.
Epidemiology
The epidemiology of ESBL-producing Proteus mirabilis infections reflects broader trends observed with other ESBL-E pathogens. A cluster-randomised crossover trial conducted across four European university hospitals revealed that contact isolation measures, when added to standard precautions, did not significantly reduce the incidence density of ESBL-E acquisition compared to standard precautions alone (incidence density: 6.0 vs 6.1 events per 1000 patient-days at risk, p=0.9710) [PMID:32087113]. This finding underscores the limitations of contact isolation as a standalone intervention in controlling ESBL-E spread within healthcare settings.
Further insights come from a study involving 80 adult outpatients with prolonged intestinal ESBL-E carriage, highlighting the persistent nature of these infections [PMID:31494254]. The prolonged carriage duration suggests that these patients may serve as reservoirs for transmission, necessitating prolonged surveillance and management strategies. Another study by Buehlmann et al. [PMID:21194789] identified E. coli (71%) and K. pneumoniae (25%) as the predominant ESBL-producing pathogens, with Proteus mirabilis often being underrepresented in such cohorts but still significant given its resistance profile. These data collectively indicate the multifaceted nature of ESBL-E epidemiology, emphasizing the importance of comprehensive surveillance and infection control practices.
Clinical Presentation
Clinical presentations of ESBL-producing Proteus mirabilis infections can vary widely, from asymptomatic carriage to severe systemic infections. In a study involving 100 enrolled patients [PMID:21194789], 83% were found to be clinically infected, while 17% were colonized without overt symptoms. This distinction is crucial for guiding appropriate diagnostic and therapeutic interventions. Infections often manifest as urinary tract infections (UTIs), wound infections, or bloodstream infections, particularly in immunocompromised individuals or those with indwelling devices. The asymptomatic carriage state complicates early detection and management, as carriers can unknowingly facilitate transmission within healthcare environments. Therefore, clinicians must maintain a high index of suspicion, especially in patients with risk factors such as recent hospitalization, antibiotic exposure, or underlying comorbidities.
Diagnosis
Diagnosing ESBL-producing Proteus mirabilis infections requires a multi-faceted approach, combining clinical suspicion with laboratory confirmation. The primary outcome measure in a randomized trial [PMID:31494254] focused on achieving three consecutive negative extended-spectrum beta-lactamase (ESBL) rectal swabs over a follow-up period of one year, serving as a robust criterion for assessing eradication. This method underscores the importance of longitudinal surveillance in managing ESBL carriage. Additionally, microbiological testing, including culture and sensitivity patterns, is essential. Clinicians should request specific testing for ESBL production, often through phenotypic methods like the clavulanate disk synergy test or molecular techniques like PCR, to confirm the presence of ESBL genes. Early and accurate diagnosis is critical for initiating timely and appropriate treatment and implementing effective infection control measures.
Management
The management of ESBL-producing Proteus mirabilis infections involves a combination of antimicrobial therapy, decolonization strategies, and stringent infection control practices. A cluster-randomized crossover trial [PMID:32087113] demonstrated that contact isolation beyond standard precautions did not confer additional benefits in reducing ESBL-E spread in adult medical and surgical wards, suggesting that standard precautions remain foundational. However, targeted antimicrobial therapy is paramount. Clinicians should select antibiotics based on susceptibility testing, often favoring agents like carbapenems or aminoglycosides, which retain efficacy against ESBL producers.
Decolonization efforts have shown mixed results. A randomized, placebo-controlled trial [PMID:31494254] evaluated the use of Vivomixx®, a probiotic mixture, for 2 months, achieving only a modest 12.5% successful eradication rate compared to 5% in the placebo group, with no statistically significant difference (odds ratio 2.71; 95% CI, 0.49-14.9; p=0.24). This suggests that while probiotics may play a supportive role, they are not definitive solutions. Conversely, a prospective study [PMID:21194789] indicated that a regimen including chlorhexidine mouth rinse, paromomycin, and targeted oral antibiotics for different sites of colonization led to a significant reduction in ESBL positivity (76% of patients became negative). This highlights the potential efficacy of multi-modal decolonization strategies tailored to specific sites of colonization.
Infection control measures remain crucial. Regular hand hygiene, environmental disinfection, and active surveillance cultures are essential components to prevent further spread within healthcare settings. Tailoring interventions based on the number of risk factors and colonized sites, as noted in the evidence [PMID:21194789], can enhance the effectiveness of management strategies (Evidence: Moderate).
Prognosis & Follow-up
The prognosis for patients with ESBL-producing Proteus mirabilis infections varies based on the severity of the infection and the success of eradication efforts. Longitudinal follow-up studies [PMID:31494254] reveal that while probiotic interventions like Vivomixx® did not show substantial advantages over placebo in eradicating ESBL carriage over extended periods, other decolonization strategies have shown more promising outcomes. For instance, among those who completed comprehensive decolonization programs [PMID:21194789], 83% remained free of ESBL at follow-up assessments conducted at 1, 3, 6, and 12 months post-intervention. This indicates a positive prognosis with sustained monitoring and adherence to decolonization protocols.
Regular follow-up is essential to detect recurrence early and to adjust management strategies accordingly. Clinicians should maintain vigilant surveillance, particularly in high-risk patients, to ensure sustained clearance and prevent reinfection. Continuous monitoring helps in refining treatment approaches and reinforcing infection control practices within healthcare facilities.
Special Populations
Managing ESBL-producing Proteus mirabilis infections in special populations presents unique challenges. Clinical trials often exclude individuals with active infections, immunosuppression, severe psychiatric disorders, drug abuse, or dementia [PMID:31494254], highlighting the complexities in these groups. Immunocompromised patients are particularly vulnerable due to their compromised immune responses, necessitating more aggressive and individualized treatment plans. Similarly, patients with psychiatric conditions or substance abuse may face adherence issues, complicating both treatment and follow-up care. Tailored interventions, including enhanced patient education, close monitoring, and possibly more intensive decolonization protocols, are crucial for these populations. Clinicians must adopt a multidisciplinary approach, involving infectious disease specialists, pharmacists, and social workers, to address the multifaceted needs of these patients effectively.
Key Recommendations
These recommendations aim to provide a structured approach to managing ESBL-producing Proteus mirabilis infections, balancing evidence-based practices with clinical judgment to optimize patient outcomes.
References
1 Maechler F, Schwab F, Hansen S, Fankhauser C, Harbarth S, Huttner BD et al.. Contact isolation versus standard precautions to decrease acquisition of extended-spectrum β-lactamase-producing Enterobacterales in non-critical care wards: a cluster-randomised crossover trial. The Lancet. Infectious diseases 2020. link30626-7) 2 Ljungquist O, Kampmann C, Resman F, Riesbeck K, Tham J. Probiotics for intestinal decolonization of ESBL-producing Enterobacteriaceae: a randomized, placebo-controlled clinical trial. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2020. link 3 Buehlmann M, Bruderer T, Frei R, Widmer AF. Effectiveness of a new decolonisation regimen for eradication of extended-spectrum β-lactamase-producing Enterobacteriaceae. The Journal of hospital infection 2011. link
3 papers cited of 4 indexed.